Pipeline
Our pipeline is built on a differentiated understanding of innate immunity to treat cancer and autoimmune diseases.
ASD141, a first-in-class innate immune checkpoint inhibitor, enhances anti-tumor immunity by blocking TLT-1/CD11b signaling and reprogramming the tumor microenvironment. ASD001 restores immune balance in autoimmune diseases by activating CD11b to regulate hyperactive myeloid cells.
Together, our programs represent a new class of immunotherapies driven by innate immune modulation.
ASD141 – Innate ICI for immuno-oncology
ASD141 is a first-in-class innate immune checkpoint inhibitor designed to reprogram the tumor microenvironment and drive coordinated anti-tumor immune responses.
In preclinical models, ASD141 demonstrated statistically significant tumor growth inhibition as a monotherapy, and enhanced efficacy and survival when combined with anti-PD-1 and anti-CTLA-4 therapies.
ASD141 is currently in a first-in-human Phase I clinical trial, where it has shown a favorable safety profile and early signals of clinical activity, including multiple cases of stable disease.
ASD001 – Innate Immune Modulator for Autoimmune Diseases
ASD001 is a first-in-class monoclonal antibody targeting the innate immune checkpoint CD11b, designed to selectively rebalance overactive myeloid cells without broad immunosuppression. Currently in preclinical development, it is being advanced for autoimmune diseases including SLE and IBD, where significant unmet need remains.
Partner of Choice for Immunotherapy Innovation
Ascendo Biotechnology is a partner of choice for novel immunotherapies targeting the interplay between innate and adaptive immunity.
We are actively seeking strategic partners to accelerate the development and commercialization of ASD141 and ASD001.
To explore partnership opportunities, please contact us.